Stefan Laufer

20.1k total citations · 4 hit papers
469 papers, 15.2k citations indexed

About

Stefan Laufer is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Stefan Laufer has authored 469 papers receiving a total of 15.2k indexed citations (citations by other indexed papers that have themselves been cited), including 271 papers in Molecular Biology, 190 papers in Organic Chemistry and 77 papers in Oncology. Recurrent topics in Stefan Laufer's work include Melanoma and MAPK Pathways (113 papers), Synthesis and biological activity (101 papers) and Inflammatory mediators and NSAID effects (47 papers). Stefan Laufer is often cited by papers focused on Melanoma and MAPK Pathways (113 papers), Synthesis and biological activity (101 papers) and Inflammatory mediators and NSAID effects (47 papers). Stefan Laufer collaborates with scholars based in Germany, Brazil and United States. Stefan Laufer's co-authors include Matthias Gehringer, Florian Läng, Pierre Koch, Caterina Faggio, Gerd K. Wagner, Meinrad Gawaz, Oliver Borst, Evi Schmid, Patrick Münzer and Britta Walker and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of the American Chemical Society.

In The Last Decade

Stefan Laufer

455 papers receiving 14.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Skepinone-L, a Novel Potent and Highly Selective Inhibitor of p38 MAP Kinase, Effectively Impairs Platelet Activation and Thrombus Formation

2013 1.5k citations Caterina Faggio, Stefan Laufer et al. Cellular Physiology and Biochemistry profile →
Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease

1998 609 citations Stefan Laufer et al. profile →
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology

2018 502 citations Matthias Gehringer, Stefan Laufer Journal of Medicinal Chemistry profile →
Candidate drugs against SARS-CoV-2 and COVID-19

2020 395 citations Stefan Laufer, Cord Naujokat et al. profile →

Peers

Countries citing papers authored by Stefan Laufer

Since Specialization

Citations

This map shows the geographic impact of Stefan Laufer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan Laufer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan Laufer more than expected).

Fields of papers citing papers by Stefan Laufer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan Laufer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan Laufer. The network helps show where Stefan Laufer may publish in the future.

Co-authorship network of co-authors of Stefan Laufer

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan Laufer. A scholar is included among the top collaborators of Stefan Laufer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan Laufer. Stefan Laufer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structure–Activity Relationships of Inactive‐Conformation Binding EGFR Inhibitors: Linking the ATP and Allosteric Pockets 2025 ·Archiv der Pharmazie ·(unknown), (unknown), Mareike Möllers, Torbjörn Hartman, Marcel Günther, Michael J. Eck, Stefan Laufer, David E. Heppner	0
2	An overview of progress in human metapneumovirus (hMPV) research: Structure, function, and therapeutic opportunities 2025 ·Drug Discovery Today ·Nadine Krüger, Stefan Laufer, Thanigaimalai Pillaiyar	3
3	Influence of design parameters on sustained drug release properties of 3D-printed theophylline tablets 2024 ·International Journal of Pharmaceutics ·(unknown), (unknown), Markus Dachtler, (unknown), Stefan Laufer, Dominique Jasmin Lunter	6
4	Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S _N Ar Electrophiles 2024 ·Journal of Medicinal Chemistry ·(unknown), (unknown), (unknown), Ramona Rudalska, (unknown), Martin P. Schwalm, (unknown), B.J. Wagner, Stefan Laufer, Stefan Knapp, Daniel Dauch, Matthias Gehringer	14
5	Probing the Protein Kinases′ Cysteinome by Covalent Fragments 2024 ·Angewandte Chemie International Edition ·(unknown), (unknown), (unknown), Yufeng Pan, (unknown), (unknown), Benedict‐Tilman Berger, (unknown), (unknown), Michael Förster, Stefan Laufer, A. Chaikuad, Matthias Gehringer, Stefan Knapp	5
6	Ready-to-use nanopore platform for label-free small molecule quantification: Ethanolamine as first example 2023 ·Nanomedicine Nanotechnology Biology and Medicine ·(unknown), (unknown), Lars Kaiser, Stefan Laufer, René Csük, (unknown), Matthias Kohl, Hans‐Peter Deigner	5
7	MKK4 Inhibitors—Recent Development Status and Therapeutic Potential 2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), Stefan Laufer	14
8	The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation 2023 ·ChemMedChem ·Jean Quancard, Anna Vulpetti, Anders Bach, Brian J. Cox, Stéphanie M. Guéret, Ingo V. Hartung, Hannes F. Koolman, Stefan Laufer, (unknown), Gianluca Sbardella, (unknown)	6
9	Toward more sustainable enzyme reactions: enhancing kinetics by polydimethylacrylamide implementation 2023 ·Green Chemistry ·(unknown), (unknown), René Csük, Stefan Laufer, Hans‐Peter Deigner	1
10	HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents 2023 ·European Journal of Medicinal Chemistry ·(unknown), (unknown), Marina Candido Primi, (unknown), Claudia Ruiz, Thales Kronenberger, Stefan Laufer, Márcia Inês Goettert, Antti Poso, (unknown), (unknown), (unknown), Neuza Mariko Aymoto Hassimotto, Michael D. Cameron, Thomas D. Bannister, Letícia V. Costa‐Lotufo, João Agostinho Machado‐Neto, Maurício T. Tavares, Roberto Parise‐Filho	4
11	Isolation and Identification of Phytocompounds from Maytenus dhofarensis and Their Biological Potentials 2023 ·Molecules ·(unknown), (unknown), (unknown), John Husband, (unknown), Márcia Inês Goettert, Stefan Laufer, Younis Baqi, Syed Imran Hassan, Majekodunmi O. Fatope	1
12	Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical Probe 2021 ·Journal of Medicinal Chemistry ·(unknown), Benedict‐Tilman Berger, Martin Schröder, Deep Chatterjee, Sebastian Mathea, Andreas C. Joerger, Daniel M. Pinkas, Joshua C. Bufton, (unknown), (unknown), (unknown), Christian Pohl, Alex N. Bullock, Susanne Müller, Stefan Laufer, Stefan Knapp	5
13	Methacryloyl-GlcNAc Derivatives Copolymerized with Dimethacrylamide as a Novel Antibacterial and Biocompatible Coating 2021 ·Pharmaceutics ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Markus Egert, Stefan Laufer, René Csük, Hans‐Peter Deigner	4
14	c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer’s Diseases 2020 ·International Journal of Molecular Sciences ·(unknown), Fernanda Majolo, Márcia Inês Goettert, Stefan Laufer	40
15	Antimicrobial and antileukemic effects: in vitro activity ofCalyptranthes grandifoliaaqueous leaf extract 2020 ·Journal of Toxicology and Environmental Health ·Fernanda Majolo, Shanna Bitencourt, (unknown), Gabriela Viegas Haute, Celso Alves, Joana Silva, Susete Pintéus, Roberto Christ Vianna Santos, Heron Fernandes Vieira Torquato, Edgar Julian Paredes‐Gamero, Jarbas Rodrigues de Oliveira, Cláucia Fernanda Volken de Souza, Rui Pedrosa, Stefan Laufer, Márcia Inês Goettert	23
16	Selective targeting of the αC and DFG-out pocket in p38 MAPK 2020 ·European Journal of Medicinal Chemistry ·(unknown), Martin Schröder, (unknown), Caroline S. Widdowson, A. Chaikuad, Benedict‐Tilman Berger, Andreas C. Joerger, Andreas Krämer, Jule Harbig, Daniel Dauch, (unknown), Stefan Laufer, Mark C. Bagley, Stefan Knapp	20
17	Fast Iterative Synthetic Approach toward Identification of Novel Highly Selective p38 MAP Kinase Inhibitors 2019 ·Journal of Medicinal Chemistry ·(unknown), Benedict‐Tilman Berger, Martin Schröder, A. Chaikuad, (unknown), Koen F. W. Hekking, (unknown), Gerhard Müller, Roberta Tesch, (unknown), Michael Förster, Stefan Laufer, Stefan Knapp	19
18	Fucoxanthin Induced Suicidal Death of Human Erythrocytes 2015 ·Cellular Physiology and Biochemistry ·Marilena Briglia, (unknown), Elena Signoretto, Kousi Alzoubi, Stefan Laufer, Caterina Faggio, Florian Läng	30
19	Targeting Cancer Stem Cells with Defined Compounds and Drugs 2013 ·Cord Naujokat, Stefan Laufer	16
20	Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4- chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid. 1995 ·PubMed ·Stefan Laufer, S. Tries, (unknown), (unknown), W. Albrecht, (unknown), (unknown), (unknown), (unknown)	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact